| Previous Close | 173.39 |
| 1-Year Change | 148.77% |
| 6-Months Change | 39.85% |
| 3-Months Change | 13.02% |
| Moving Avg (50d) | 168.31 |
| Moving Avg (200d) | 131.26 |
| ESG Rating | - |
| Exchange | NASDAQ |
| Market Cap. | 20.6B |
| Beta (3-Years) | 1.47 |
| Revenue Growth (ttm) | 27.41% |
| Net Profit Margin (ttm) | -50.5% |
| Return On Assets (ttm) | -34.52% |
| EPS (ttm) | -4.52 |
| PE Ratio (ttm) | -38.36 |
| Dividend Yield | % |
Ask ChatGPT ?
This might take more than 30s in the first call...
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
| Sector: | Health Care |
| Industry: | Life Sciences Tools & Services |
| Country: | United States |
Natera, Inc. is a clinical genetic testing company based in Austin, Texas that specializes in non-invasive, cell-free DNA testing technology, with a focus on women’s health, cancer, and organ health. Natera’s proprietary technology combines novel molecular biology techniques with a suite of bioinformatics software that allows detection down to a single molecule in a tube of blood. Natera operates CAP-accredited... Wikipedia